NVIDIA Corp (NVDA)

This cloud computing stock has more than doubled in 2025, and it still has room to rise.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Spotify and Howmet Aerospace are already actionable.

Are these two companies poised to rack up huge AI wins over the next half-decade?

TSMC is set to benefit from continued massive spending in AI.

The tie-up could help Intel increase revenue and Nvidia decrease supply chain risk.

The market is full of reasonably priced AI investments, but Palantir isn't one of them.

Taiwan Semiconductor is the world's largest semiconductor foundry by far.

Billionaire investors were piling into these names in Q2.

NVIDIA (NVDA) excels with strong AI-driven growth, high profitability, and a promising technical breakout setup, making it a top growth and momentum stock.

Its experimental tech could solve OpenAI's biggest barrier to success.

Early sales reports show this semiconductor giant far outpacing third-quarter expectations.

Hedge fund manager Ken Griffin continued to sell Tesla in the second quarter, but he bought a substantial position in Nvidia.

Broadcom, TSMC, and ASML are three top artificial intelligence (AI) stocks to buy now.

Perspectives and risk tolerances could drive this choice.

These companies are set to benefit from this wave of AI growth.

Former Intel board member is proposing a government-backed privatization to unlock shareholder value after Nvidia's $5 billion investment.

Microsoft just inked a $17.4 billion deal with a data center company backed by Nvidia.

Beth Kindig of the I/O Fund thinks Nvidia will become a $6 trillion stock by next year.

Do investors need to be worried about Micron's sell-off today?

Tesla's CEO recently made a bold statement about the company's progress on designing its own artificial intelligence chips.

Did Nvidia just throw $5 billion out the window on Intel?

Shares of logistics and freight forwarding company Expeditors (NYSE:EXPD) fell 2.8% in the afternoon session after investors reacted to an 'underweight' rating from Barclays and digested ongoing concerns about the company's weak financial performance. 

Shares of pool products retailer Leslie’s (NASDAQ:LESL) fell 4.6% in the afternoon session after traders reacted to a series of cautious analyst notes, including a steep price target reduction from Mizuho. 

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder.